813 Insulin-like growth factor-binding protein 5 alleviates skin inflammation in psoriasis mice model

Antimicrobial peptide derived from insulin-like growth factor-binding protein 5 (AMP-IBP5) is expressed in keratinocytes and displays both antimicrobial immunomodulatory properties. In contrast to many peptides (AMPs), factor-binging 5, the parent of AMP-IBP5, downregulated psoriasis, an inflammatory skin disease characterized by epidermal hyperplasia, erythematous plaques, abnormal differentiation, neutrophil infiltration interleukin (IL)-17 overproduction into psoriatic lesions. Although several AMPs have been implicated pathogenesis role AMP-IBP5 remains unknown. This study aimed investigate effects psoriasis using imiquimod-induced psoriastic mouse model. Following subcutaneous administration mice, reduced presence dry scales thickness, hyperkeratosis, parakeratosis, hyperplasia dermal vessels IL-17+ T cell infiltration, compared with normal mice. Consistently, diminished expression cytokine TNF-α, such as cathelicidin CRAMP S100A proteins, angiogenesis factors, including vascular endothelial factor platelet-derived lesional skin. Interestingly, receptor-associated (RAP), antagonist low-density lipoprotein receptor-related 1 (LRP1), exacerbated abolished AMP-IBP5-mediated improvement psoriasis. indicates that LRP1 may play a crucial improve via signaling pathway. Collectively, we provide evidence might be novel potential therapeutic target for treatment